53 studies found for:    dira
Show Display Options
Rank Status Study
1 Recruiting Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
2 Completed Topical IL-1-Ra for Treatment of Corneal Neovascularization
Condition: Corneal Neovascularization
Interventions: Drug: Placebo;   Drug: IL-1Ra
3 Completed
Has Results
Topical IL-1-Ra for Treatment of Posterior Blepharitis
Condition: Posterior Blepharitis
Interventions: Drug: 2.5% IL-1Ra;   Drug: Placebo;   Drug: 5% IL-1Ra
4 Completed Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
Condition: Type 2 Diabetes
Intervention: Drug: IL-1Ra
5 Recruiting Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
6 Completed
Has Results
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: CP-690,550 + methotrexate;   Drug: Placebo + Methotrexate
7 Recruiting Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Conditions: Chronic Kidney Disease;   Cardiovascular Disease
Interventions: Drug: Rilonacept;   Drug: Placebo
8 Recruiting Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic
Condition: Hodgkin's Disease
Intervention: Other: Collection of blood specimen
9 Completed Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise
Condition: Type 2 Diabetes
Interventions: Drug: IL-1Ra;   Drug: Placebo
10 Active, not recruiting Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy
Condition: Knee Injuries
Intervention: Drug: Anakinra 100 mg in 2 ml saline IA
11 Completed Study to Prevent Cartilage Damage Following Acute Knee Injury.
Condition: Knee Injury
Intervention: Drug: Anakinra
12 Terminated The SPECTRA Study
Condition: Rheumatoid Arthritis
Interventions: Drug: anakinra;   Drug: anakinra and PEG sTNF-R1
13 Completed Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
Condition: Systemic-Onset Juvenile Idiopathic Arthritis
Interventions: Drug: Anakinra;   Biological: Pneumo23
14 Not yet recruiting Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.
Condition: Chronic Low Back Pain
Intervention:
15 Completed Investigating Cytokine Genes of Stem Cell Donors
Condition: Stem Cell Transplantation
Intervention:
16 Completed Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery
Condition: Joint Instability
Intervention: Procedure: ACL reconstructive surgery and ACS/ Orthokin application
17 Completed
Has Results
Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
Condition: End Stage Renal Disease
Interventions: Drug: kineret;   Drug: placebo
18 Completed
Has Results
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: Anakinra (IL-1Ra);   Drug: Dexamethasone acetate
19 Unknown  Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients
Conditions: Electric Impedance;   Metabolic Expenditure and Respiratory Function.;   Polymorphisms Determinations of the Genes for TNF-alfa(-863 e -308), IL-1ra, LTalfa, IL-6, MIF e IL10.;   Cytokines Measurement;   NF-kappa B Activation.
Intervention:
20 Completed Anti-Interleukin-1 in Diabetes Action
Condition: Type 1 Diabetes
Interventions: Drug: anakinra;   Drug: saline

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years